Evidence map›Paper›PMID 26254777›Full record

ArticleEuropean journal of clinical pharmacology2015

Anticholinergic burden in Parkinson's disease inpatients.

Unax Lertxundi, Arantxazu Isla, Maria Angeles Solinis, Saioa Domingo-Echaburu, Rafael Hernandez, Javier Peral-Aguirregoitia, Juan Medrano

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Evaluation of anticholinergic burden in elderly outpatients and the risk factors.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.International journal of molecular sciences · 2017
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Unax LertxundiPharmacy Service, Araba's Mental Health Network, C/alava 43, 01006, Vitoria-Gasteiz, Alava, Spain. unax.lertxundietxebarria@osakidetza.net.
Arantxazu IslaPharmacy and Pharmaceutic Technology Department, Pharmacy Faculty, University of theBasque Country UPV/EHU, Paseo de laUniversidad 7, 01006, Vitoria-Gasteiz, Araba/Álava, Spain. arantxa.isla@ehu.es.
Maria Angeles SolinisPharmacy and Pharmaceutic Technology Department, Pharmacy Faculty, University of theBasque Country UPV/EHU, Paseo de laUniversidad 7, 01006, Vitoria-Gasteiz, Araba/Álava, Spain. marian.solinis@ehu.es.
Saioa Domingo-EchaburuPharmacy Service, Alto Deba Integrated Health Organization, Avda. Nafarroa, 16, 20500, Arrasate, Gipuzkoa, Spain.
Rafael HernandezInternal Medicine Service, Araba´s Mental Health Network, C/alava 43, 01006, Vitoria-Gasteiz, Alava, Spain. rafael.hernandezpalacios@osakidetza.net.
Javier Peral-AguirregoitiaPharmacy Service, Hospital Galdakao-Usánsolo, Barrio labeaga s/n., Galdakao, Vizcaya, Spain. javier.peralaguirregoitia@osakidetza.net.
Juan MedranoPsychiatry Service, Bizkaia´s Mental Health Network, Portugalete, Spain. juan.medranoalbeniz@osakidetza.net.
Hospital Universitario Araba · ESUniversity of the Basque Country · ESHealth Net · USHospital Alto Deba · ESHospital de Galdakao · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnticholinergic toxicity can arise as a result of the cumulative burden of multiple medications and metabolites rather than be caused by a single compound. In this sense, prescribing drugs with anticholinergic properties to Parkinson's disease (PD) patients could contribute to aggravate some frequent problems of the disease, like dementia, urinary retention, falls, or constipation, among others. The main purpose of this article is to measure the total anticholinergic burden in a group of PD inpatients.

methodWe analyzed information from different administrative Basque Country's healthcare databases using encrypted unique identifiers in order to detect PD patients admitted to public acute care hospital during 2011-2012. Subsequently, anticholinergic burden was measured using Duran et al.'s list. Secondarily, total anticholinergic load was assessed with the Anticholinergic Drug Scale, the Anticholinergic Risk Score, and the Anticholinergic Burden Scale. A logistic regression model was performed to study association of predictive variables with anticholinergic use.

resultsA high proportion of PD patients were prescribed anticholinergic drugs, with 53.6% of admissions receiving at least one drug from Duran et al.'s "low-risk" and 10% at least "high-risk" drug. Drugs used for non-motor symptoms and other comorbidities other than PD itself contributed significantly to anticholinergic burden, namely antidepressants, antipsychotics, urological drugs, analgesics, and antihistamines, among others. The total number of drugs and cholinesterase inhibitors were independently associated with anticholinergic drug use.

conclusionsAnticholinergic burden in PD patients is significant, and is caused mostly by drugs not used for PD motor symptoms. Polypharmacy and cholinesterase inhibitors were independently associated with anticholinergic drug prescriptions.

Indexed as

AgedAged, 80 and overAge FactorsCholinergic AntagonistsCholinesterase InhibitorsComorbidityDementiaDrug UtilizationFemaleHospitalizationHumansLength of StayLogistic ModelsMaleParkinson DiseasePolypharmacyCholinergic AntagonistsCholinesterase InhibitorsCholinergics/antagonists adverse effectsCholinesterase inhibitorsHospitalizationParkinson’s diseasePolypharmacy

Identifiers

PMID26254777
OpenAlexW1823175426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.